logo
Book a meeting
Orpro Therapeutics

Orpro Therapeutics

Biotechnology, 3210 Merryfield Row, SAN DIEGO, California, 92121, United States, 1-10 Employees

orprotherapeutics.com

  • facebook
  • twitter
  • LinkedIn

Who is ORPRO THERAPEUTICS

OrPro Therapeutics, Inc. is a San Diego preclinical-stage Johnson & Johnson JLABS alumni company addressing large unmet medical needs in acute and chronic respiratory, ophthalmology, and ...

Read More

lock icon Get Full Access
map
  • 3210 Merryfield Row, SAN DIEGO, California, 92121, United States Headquarters: 3210 Merryfield Row, SAN DIEGO, California, 92121, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • Peter Heifetz CEO:   Peter Heifetz

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from ORPRO THERAPEUTICS

Orpro Therapeutics Org Chart and Mapping

Peter Heifetz

Peter Heifetz

Chief Executive Officer

See Full Org Chart arrow
email-formate-icon
View Email Formats for Orpro Therapeutics
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Orpro Therapeutics

Answer: Orpro Therapeutics's headquarters are located at 3210 Merryfield Row, SAN DIEGO, California, 92121, United States

Answer: Orpro Therapeutics's official website is https://orprotherapeutics.com

Answer: Orpro Therapeutics's revenue is Under $1 Million

Answer: Orpro Therapeutics's SIC: 2834

Answer: Orpro Therapeutics has 1-10 employees

Answer: Orpro Therapeutics is in Biotechnology

Answer: Orpro Therapeutics contact info: Phone number: Website: https://orprotherapeutics.com

Answer: OrPro Therapeutics, Inc. is a San Diego preclinical-stage Johnson & Johnson JLABS alumni company addressing large unmet medical needs in acute and chronic respiratory, ophthalmology, and oncology with a cell-protective biologic drug platform based on the secreted human protein thioredoxin. Lead asset ORP100S has been shown to reduce inflammation, normalize mucociliary functions, and mitigate adverse effects of chemotherapy and radiation on stem cells in bone marrow and other sensitive organs through a novel covalent-binding mechanism that opens up disease-modifying treatment opportunities in obstructive, oxidative and inflammatory disorders, vision-threatening diseases of the retina, and cancer therapy.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access